GoInVivo™ Purified anti-human CD279 (PD-1) A
- 产品名称：
- GoInVivo™ Purified anti-human CD279 (PD-1) A
- 产品类别：
- 抗体
- 产品编号：
- 329946
- 产品应用：
- 329946
- Verified Reactivity
- Human, African Green, Baboon, Chimpanzee, Common Marmoset, Cynomolgus, Rhesus, Squirrel Monkey
- Antibody Type
- Monoclonal
- Host Species
- Mouse
- Formulation
- 0.2 ?m filtered in phosphate-buffered solution, pH 7.2, containing no preservative. Endotoxin level is <1.0 EU/mg of the protein. (<0.1 pg/?g of the protein) as determined by the LAL test.
- Preparation
- The GoInVivo? antibody was purified by affinity chromatography.
- Concentration
- The antibody is bottled at the concentration indicated on the vial, typically between 2 mg/mL and 3 mg/mL.
- Storage & Handling
- The antibody solution should be stored undiluted between 2°C and 8°C. This GoInVivo? solution contains no preservative; handle under aseptic conditions.
- Application
-
FC - Quality tested
Block, IHC - Reported in the literature, not verified in house
- Recommended Usage
Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤1.0 ?g per million cells in 100 ?l volume or 100 ?l of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.
For in vivo and in vitro applications, we recommend to perform a pilot experiment to determine the optimal concentration to use for each particular experiment.
- Application Notes
GoInVivo? products are guaranteed to be pathogen-free based on the IDEXX BioResearch IMPACT test via PCR. For a full listing of pathogens tested, visit the GoInVivo? Webpage.
Additional reported applications (for the relevant formats) include: blocking of ligand binding1-3 and immunohistochemical staining of paraformaldehyde fixed frozen sections13.
- Application References
(PubMed link indicates BioLegend citation) -
- Dorfman DM, et al. 2006 Am. J. Surg. Pathol. 30:802. (FA)
- Radziewicz H, et al. 2007. J. Virol. 81:2545. (FA)
- Velu V, et al. 2007. J. Virol. 81:5819. (FA)
- Zahn RC, et al. 2008. J. Virol. 82:11577. PubMed
- Chang WS, et al. 2008. J. Immunol. 181:6707. (FC) PubMed
- Nakamoto N, et al. 2009. PLoS Pathog. 5:e1000313. (FA)
- Jones RB, et al. 2009. J. Virol. 83:8722. (FC) PubMed
- Vojnov L, et al. 2010. J. Virol. 84:753. (FC) PubMed
- Radziewicz H, et al. 2010. J. Immunol. 184:2410. (FC) PubMed
- Monteriro P, et al. 2011. J. Immunol. 186:4618. PubMed
- Conrad J, et al. 2011. J. Immunol. 186:6871. PubMed
- Salisch NC, et al. 2010. J. Immunol. 184:476. (Rhesus reactivity)
- Li H and Pauza CD. 2015. Eur. J. Immunol. 45:298. (IHC)
- Product Citations
-
- Kwon M, et al. 2020. Clin Cancer Res. 1644:26. PubMed
- Zou F, et al. 2019. Nat Commun. 10:4109. PubMed
- RRID
- AB_2566290 (BioLegend Cat. No. 329946) AB_2566291 (BioLegend Cat. No. 329947) AB_2566292 (BioLegend Cat. No. 329948) AB_2565904 (BioLegend Cat. No. 329943) AB_2566078 (BioLegend Cat. No. 329944) AB_2566079 (BioLegend Cat. No. 329945)
- Structure
- Immunoglobulin superfamily
- Distribution
-
Transiently expressed on CD4- CD8- thymocytes; upregulated in thymocytes and splenic T and B lymphocytes; expressed on activated myeloid cells
- Ligand/Receptor
- B7-H1 (also known as PD-L1) and B7-DC (PD-L2)
- Cell Type
- B cells, T cells, Thymocytes, Tregs
- Biology Area
- Cancer Biomarkers, Immunology, Inhibitory Molecules
- Molecular Family
- CD Molecules, Immune Checkpoint Receptors
- Gene ID
- 5133 View all products for this Gene ID
- UniProt
- View information about CD279 on UniProt.org
